Constrictive Pericarditis vs. Restrictive Cardiomyopathy: The Diagnostic Puzzle Where the Right Answer Changes Everything

Two patients walk into clinic on the same day with similar stories. Both are short of breath. Both have leg swelling. Both have a normal-looking left ventricular ejection fraction on echocardiogram. Both have elevated jugular venous pressure on examination. The first patient has had cardiac surgery in the past. The second has a paraprotein on a routine blood panel. Their physical exams look almost identical. Their echos look broadly similar. And yet the right diagnosis for each one points to a completely different treatment plan, with one curable by surgery and the other often progressive despite our best efforts.

I'm Dr. Damian Rasch, a cardiologist in Encinitas. The distinction between constrictive pericarditis and restrictive cardiomyopathy is one of the classic diagnostic challenges in cardiology, and getting it right matters enormously. Constrictive pericarditis can often be cured with pericardiectomy, a major operation that removes the diseased pericardium and lets the heart fill normally again. Restrictive cardiomyopathy, depending on the cause, ranges from treatable (cardiac amyloidosis with newer agents, sarcoidosis with immunosuppression) to a course that ends in transplant. The two diseases produce remarkably similar physiology, and they look so much alike that they are easy to confuse, but they are biologically distinct in ways that change the entire trajectory of care. This article walks through how to think about each, how we tell them apart, and what the management looks like once the diagnosis is clear.

The Same Final Common Pathway, Two Different Causes

Both constrictive pericarditis and restrictive cardiomyopathy produce a hemodynamic picture called diastolic heart failure, sometimes also called heart failure with preserved ejection fraction (HFpEF). The heart's pumping function is normal or near-normal, but the heart can't fill properly during diastole. Blood backs up behind the heart, the patient develops elevated filling pressures, and symptoms of fluid overload develop.

The difference between the two diseases is where the failure to fill comes from. In constrictive pericarditis, the pericardium (the fibrous sac surrounding the heart) becomes thickened, scarred, sometimes calcified, and rigid. The heart inside is structurally fine. It just can't expand because the rigid pericardium won't let it. Imagine trying to fill a balloon inside a metal box. The balloon itself is fine. The problem is the box.

In restrictive cardiomyopathy, the problem is the heart muscle itself. The muscle has become stiff, often because of an infiltrative process depositing abnormal material in the myocardium (amyloid, granulomas in sarcoidosis, iron in hemochromatosis, fibrous tissue in endomyocardial fibrosis, eosinophilic infiltration in hypereosinophilic syndrome). The muscle can't relax and stretch the way normal muscle does, so the ventricle can't fill, even with a normal pericardium around it.

Both produce the same downstream picture: high filling pressures, fluid backing up into the lungs and the systemic veins, leg swelling, ascites, and eventually low cardiac output despite a normal ejection fraction. The pathophysiology converges, but the underlying biology diverges sharply, and so does the treatment.

Why Getting It Right Matters So Much

The reason this distinction is worth doing thoroughly is that the treatments are not interchangeable.

Constrictive pericarditis is potentially curable. Pericardiectomy, in which a cardiac surgeon strips the diseased pericardium off the heart, can completely reverse the constrictive physiology in many patients. The heart, freed from the rigid encasement, can fill normally again. Functional capacity improves dramatically. Patients who were severely limited can return to near-normal exercise tolerance. The operation is a major one (cardiopulmonary bypass, careful dissection of pericardium adherent to the epicardium, sometimes complicated postoperative recovery), but the upside, when the diagnosis is right, is substantial.

Restrictive cardiomyopathy is a different problem. There is no equivalent surgical cure. Treatment is targeted at the underlying cause: tafamidis or vutrisiran for transthyretin amyloidosis, daratumumab-based regimens for AL amyloidosis, immunosuppression for sarcoidosis, phlebotomy for hemochromatosis, steroids for hypereosinophilic syndrome. Some restrictive cardiomyopathies, especially cardiac amyloidosis caught early, can be stabilized or even improved with modern therapies. Others, especially advanced cases, eventually progress to require heart transplantation. Standard heart failure medications (ACE inhibitors, ARBs, beta-blockers) are often poorly tolerated in restrictive cardiomyopathy because the patient's hemodynamics depend on adequate preload and a relatively fast heart rate.

Mistaking restrictive cardiomyopathy for constrictive pericarditis and proceeding to pericardiectomy is a serious problem. The patient gets a major operation that doesn't help, and the underlying restrictive disease continues to progress. Mistaking constrictive pericarditis for restrictive cardiomyopathy means missing a curable disease and managing the patient with palliative diuretics for years instead of fixing the actual problem. Both errors happen. The diagnostic workup exists to prevent them.

Causes of Constrictive Pericarditis

In Western countries, the most common causes of constrictive pericarditis are prior cardiac surgery and prior chest radiation. The pericardium gets inflamed at the time of these interventions, and over months to years it can scar down into a rigid encasing layer. Patients with a history of coronary artery bypass grafting from twenty years ago or chest radiation for Hodgkin lymphoma in their twenties are classic constrictive pericarditis populations.

Idiopathic constrictive pericarditis, often the late sequela of viral or autoimmune pericarditis years earlier, accounts for a meaningful fraction of cases. The patient may have had a self-limited viral pericarditis episode in their thirties and then present in their fifties or sixties with constrictive physiology, with the original pericarditis long forgotten.

In other parts of the world, tuberculosis remains a major cause. TB pericarditis can resolve with treatment but leaves behind extensive scarring that produces constriction in a meaningful minority of patients. Any patient with a TB exposure history and unexplained heart failure deserves consideration of TB-related constrictive pericarditis.

Less common causes include connective tissue diseases (lupus, rheumatoid arthritis), purulent bacterial pericarditis, malignancy with pericardial involvement, post-myocardial infarction pericarditis, and uremic pericarditis from kidney failure.

Causes of Restrictive Cardiomyopathy

Cardiac amyloidosis is the most common restrictive cardiomyopathy in modern practice. Two main types: AL amyloidosis from a plasma cell dyscrasia, and ATTR amyloidosis from misfolded transthyretin. ATTR can be hereditary (a single nucleotide mutation in the transthyretin gene) or wild-type (age-related, more common in older men). The wild-type ATTR population has expanded dramatically in recent years as imaging and biomarkers have made the diagnosis easier and as treatments like tafamidis have changed the prognosis. I have a separate article on ATTR cardiac amyloidosis on the site for patients who want a deeper read on that diagnosis.

Cardiac sarcoidosis can produce a restrictive picture, especially in the early or late stages of disease. Granulomas in the myocardium replace normal contractile tissue and produce stiffness. I have a separate article on cardiac sarcoidosis on the site as well.

Hemochromatosis causes restrictive cardiomyopathy through iron deposition in the myocardium. Inherited hemochromatosis (HFE gene mutations) is the most common form, with cardiac involvement appearing later in the disease course. Phlebotomy to reduce body iron stores can stabilize or reverse early cardiac involvement.

Hypereosinophilic syndrome with cardiac involvement (Loeffler endocarditis) is rarer but distinctive, with eosinophilic infiltration of the endocardium leading to fibrosis and a restrictive picture, often with thrombus in the ventricles.

Endomyocardial fibrosis is a tropical disease, common in equatorial Africa and parts of Asia, that produces fibrous tissue deposition in the endocardium. The patient population in Western practice is mostly immigrants from endemic regions.

Glycogen and lysosomal storage diseases (Fabry, Pompe) and certain hereditary cardiomyopathies can also produce restrictive physiology. These are uncommon in adult cardiology practice but important to recognize because treatment options exist for some of them.

The Workup: Imaging First, Then Pressure Studies

When a patient presents with diastolic heart failure, elevated filling pressures, and a preserved ejection fraction, the workup proceeds in a stepwise fashion to distinguish constrictive pericarditis from restrictive cardiomyopathy.

Echocardiography

The echo is the starting point. Several features point toward constrictive physiology: respiratory variation in mitral inflow velocity greater than 25 percent (with an increase during expiration and a decrease during inspiration, opposite of the normal pattern), respiratory variation in tricuspid inflow that mirrors but in the opposite direction, septal bounce or shudder during early diastole as the ventricles compete for limited space, plethora of the inferior vena cava without inspiratory collapse, and preserved or normal tissue Doppler velocities at the mitral annulus despite high filling pressures.

Restrictive cardiomyopathy on echo shows different features: biatrial enlargement (often dramatic) from chronic high filling pressures, a small or normal left ventricular cavity size, often increased wall thickness (especially in amyloidosis where wall thickness is preserved or increased despite low voltage on EKG), and reduced tissue Doppler velocities at the mitral annulus reflecting the diseased myocardium itself. The respiratory variation seen in constriction is absent or minimal.

An experienced echocardiographer can usually narrow the diagnosis substantially with a careful study, but echo alone doesn't always settle the question.

Cardiac MRI

Cardiac MRI is excellent for both diseases. For constrictive pericarditis, MRI can directly visualize pericardial thickening (greater than 4 mm is concerning, although thickness can be normal in some constrictive cases). Real-time cine imaging can show septal flattening and shudder during inspiration, characteristic of constriction. Late gadolinium enhancement of the pericardium suggests active inflammation, sometimes seen in early constrictive disease.

For restrictive cardiomyopathy, MRI can identify the underlying tissue characteristics. Cardiac amyloidosis has a characteristic pattern of diffuse subendocardial late gadolinium enhancement, often described as "ghost myocardium." Cardiac sarcoidosis shows patchy mid-wall and subepicardial enhancement, especially in the basal septum. Hemochromatosis shows reduced T2* values from iron deposition. Hypereosinophilic syndrome shows endocardial enhancement and sometimes apical thrombus.

In many cases, MRI is the single most informative imaging study, and it should be done early in the workup of any patient with unexplained restrictive physiology.

CT

Cardiac CT is especially useful for visualizing pericardial calcification, which is highly specific for constrictive pericarditis when present. A heavily calcified pericardium on CT, in a patient with the right clinical picture, is diagnostic. CT is also useful when MRI is contraindicated or unavailable.

Right Heart Catheterization

When the imaging studies don't give a definitive answer, right heart catheterization with simultaneous left and right heart pressure measurement is the gold standard test. Several findings distinguish constrictive from restrictive physiology:

In constrictive pericarditis, the right and left ventricular end-diastolic pressures equalize within about 5 mmHg of each other, because the rigid pericardium constrains both chambers equally. In restrictive cardiomyopathy, the left-sided pressures usually exceed the right-sided pressures by more than 5 mmHg, because the disease often affects the left ventricle more severely.

In constrictive pericarditis, ventricular interdependence is exaggerated. During inspiration, the right ventricle takes more blood and the left ventricle takes less; the systolic pressures vary in opposite directions, called systolic discordance. In restrictive cardiomyopathy, both ventricles fill from a stiff myocardium independently, so the systolic pressures vary in the same direction (concordance).

Both diseases show a characteristic "dip and plateau" or "square root sign" in ventricular pressure tracings during early diastole, but the inspiratory variation in this pattern is much more pronounced in constrictive pericarditis.

An experienced invasive cardiologist can usually settle the diagnosis with a careful catheterization study, although there are still cases where the answer is ambiguous and additional imaging or biopsy is required.

Biomarkers and Specialized Testing

BNP and NT-proBNP are usually higher in restrictive cardiomyopathy than in constrictive pericarditis, because the diseased myocardium itself produces these biomarkers when stretched. A markedly elevated BNP in a patient with diastolic heart failure is more consistent with restrictive disease than with pure constriction.

For suspected amyloidosis, the workup includes serum and urine protein electrophoresis with immunofixation, free light chain assay, and a technetium pyrophosphate (PYP) scan, which is highly specific for ATTR cardiac amyloidosis when positive at grade 2 or 3 uptake. Tissue biopsy (either of the heart or of an extracardiac site like fat pad or lip salivary gland) is sometimes required to confirm and type the amyloid.

For suspected sarcoidosis, the workup includes chest CT, FDG-PET with appropriate dietary preparation, and tissue biopsy from accessible affected sites.

For suspected hemochromatosis, ferritin and transferrin saturation, then HFE gene testing if abnormal.

Treatment: The Two Diseases Diverge Sharply

Constrictive Pericarditis

Once the diagnosis of constrictive pericarditis is confirmed, the question becomes whether the patient is a candidate for pericardiectomy. The answer depends on symptom burden, functional status, surgical risk, and the underlying cause.

Patients with severe symptoms (NYHA class III or IV), preserved myocardial function (no significant systolic dysfunction or epicardial fibrosis), and reasonable surgical candidacy usually do well with pericardiectomy. The operation removes the diseased pericardium entirely, allowing the heart to fill normally. Recovery takes weeks to months, with progressive improvement in functional capacity. Long-term survival after successful pericardiectomy approaches that of age-matched controls in many series.

Patients with active inflammation (transient or "effusive-constrictive" disease) sometimes respond to anti-inflammatory therapy with NSAIDs, colchicine, or corticosteroids. A trial of medical therapy can be reasonable when the disease is in an active inflammatory phase, since some of these cases resolve without surgery. Patients with chronic, fixed constriction without active inflammation usually need surgery.

Patients with high surgical risk (advanced age, multiple comorbidities, severe pulmonary disease) or with extensive epicardial scarring (where the disease has invaded the heart muscle itself) have less favorable outcomes from pericardiectomy. In these patients, medical therapy with diuretics is sometimes the better option, accepting that the disease will continue to limit function.

Diuretics are the backbone of medical management for constrictive pericarditis when surgery is not done. Loop diuretics (furosemide, torsemide, bumetanide) reduce filling pressures and improve symptoms, although they don't address the underlying pericardial pathology. Patients on diuretics for constrictive disease often need careful titration because they sit on a narrow ledge between under-diuresis with persistent symptoms and over-diuresis with low cardiac output.

Restrictive Cardiomyopathy

Treatment of restrictive cardiomyopathy depends on the underlying cause.

For ATTR cardiac amyloidosis, tafamidis is the foundation of treatment. The ATTR-ACT trial showed that tafamidis reduces all-cause mortality and cardiovascular hospitalizations compared to placebo. Newer agents that target TTR production (vutrisiran, patisiran, eplontersen) have expanded the treatment landscape for both wild-type and hereditary ATTR. Patients diagnosed early and started on these therapies can have dramatically better outcomes than they would have had a decade ago.

For AL cardiac amyloidosis, the focus is on stopping the underlying plasma cell dyscrasia with chemotherapy, often a regimen including daratumumab, bortezomib, cyclophosphamide, and dexamethasone. Achieving a deep hematologic response can stabilize or reverse cardiac amyloid deposition.

For cardiac sarcoidosis, immunosuppression with corticosteroids and steroid-sparing agents like methotrexate is the foundation. The dedicated article on cardiac sarcoidosis goes into more detail.

For hemochromatosis, therapeutic phlebotomy reduces body iron stores. Iron chelation is added in patients who can't tolerate phlebotomy.

For hypereosinophilic syndrome, corticosteroids reduce eosinophilia. Imatinib is used when the FIP1L1-PDGFRA fusion is present. Mepolizumab and other anti-IL-5 agents have a growing role.

In all cases, standard heart failure medications need to be used cautiously. ACE inhibitors and ARBs can drop preload too aggressively. Beta-blockers can reduce the modest cardiac output reserve these patients depend on. Diuretics are useful but require careful titration. Atrial fibrillation, when it develops, is often poorly tolerated because the loss of atrial kick worsens the already compromised filling, and rhythm control is often pursued more aggressively than usual.

Heart transplantation is the ultimate option for selected patients with advanced restrictive cardiomyopathy. Outcomes after transplant are usually good, although the underlying disease can sometimes recur in the transplanted heart, depending on the cause.

Prognosis

The prognosis of constrictive pericarditis after successful pericardiectomy is favorable in most patients. Operative mortality at experienced centers is around 5 to 10 percent, with higher mortality in patients with concomitant left ventricular dysfunction or radiation-related disease. Long-term survival after recovery is good, with many patients returning to near-normal functional capacity.

The prognosis of restrictive cardiomyopathy depends heavily on the underlying cause. Wild-type ATTR amyloidosis with early treatment now has a meaningfully better prognosis than it did a decade ago, with several years of stable function achievable in many patients. AL amyloidosis with deep hematologic response can also have prolonged stability. Hemochromatosis with adequate phlebotomy can have a normal life expectancy. Cardiac sarcoidosis has a variable course depending on disease activity and response to treatment. Endomyocardial fibrosis and advanced infiltrative disease without treatment options often progress relentlessly.

In all cases, the most important determinant of long-term outcome is identifying the disease early and matching the treatment to the specific cause. Patients who get a clear diagnosis quickly and get started on appropriate therapy often do well over the long run. Patients whose diagnosis is delayed or whose disease is misclassified often present with advanced disease that's harder to manage.

When to Suspect These Diagnoses

Constrictive pericarditis should be considered in any patient with diastolic heart failure, especially when there's a history of prior cardiac surgery, chest radiation, viral or autoimmune pericarditis, or TB exposure. The patient with unexplained right-sided heart failure, elevated jugular venous pressure with a steep Y-descent, and Kussmaul's sign (jugular venous pressure that fails to drop with inspiration) on examination should have an MRI or CT looking for pericardial thickening or calcification.

Restrictive cardiomyopathy should be considered in any patient with diastolic heart failure and biatrial enlargement, especially when wall thickness is preserved or increased despite low voltage on EKG. The patient with carpal tunnel syndrome years before the heart failure, especially bilateral, should be screened for ATTR amyloidosis. The patient with a paraprotein on protein electrophoresis and unexplained heart failure should be evaluated for AL amyloidosis. The patient with a family history of cardiac disease in middle age should be considered for hereditary ATTR or hereditary hemochromatosis.

When to Escalate Care

Call 911 immediately for severe shortness of breath at rest, chest pain, syncope, or any combination of those. Both constrictive and restrictive disease can decompensate rapidly, especially when arrhythmias or volume overload occur.

Contact your cardiologist the same day for new or worsening leg swelling, weight gain of three to five pounds over a few days, increased shortness of breath, palpitations, or new fatigue. Both diseases sit on a fragile hemodynamic balance, and small changes in volume status can produce marked symptoms.

Schedule a clinic visit within one to two weeks for any concerns about treatment side effects (steroid effects in sarcoidosis, chemotherapy effects in AL amyloidosis, tafamidis tolerance in ATTR), or for routine follow-up to assess disease progression and treatment response.

Common Patient Questions

If I have constrictive pericarditis, do I really need surgery?

In most cases with substantial symptoms, yes. Pericardiectomy is the only treatment that addresses the underlying problem of a rigid encasing pericardium. Diuretics and other medical therapies treat the consequences (fluid overload) but not the cause. The decision to proceed to surgery depends on symptom severity, surgical candidacy, and the absence of contraindications. Patients with mild symptoms or with active inflammatory disease that might respond to anti-inflammatory therapy can sometimes avoid or defer surgery, but for chronic constriction with substantial functional limitation, pericardiectomy is the definitive treatment.

My echo shows preserved ejection fraction, but I feel terrible. How is that possible?

Heart failure with preserved ejection fraction is a real and serious diagnosis. The heart's pumping function (squeezing during systole) can be normal while its filling function (relaxing during diastole) is severely impaired. Constrictive pericarditis and restrictive cardiomyopathy are two of the most extreme examples of pure diastolic heart failure, but garden-variety HFpEF, often related to longstanding hypertension, diabetes, and aging, also causes severe symptoms. Don't let an "ejection fraction is preserved" report convince you that everything is fine if you have heart failure symptoms.

I had bypass surgery fifteen years ago. Could that be causing this?

Yes, prior cardiac surgery is one of the most common causes of constrictive pericarditis in Western practice. The pericardium is opened during bypass surgery, and the inflammation and adhesions that follow can, in a small fraction of patients, eventually scar down into a constrictive layer. This typically happens years after the original operation, sometimes decades later. If you have unexplained heart failure with preserved ejection fraction and a history of cardiac surgery, your cardiologist should be looking at the pericardium with imaging and considering invasive hemodynamics.

I had radiation for breast cancer in my thirties. Should I be screened?

Patients who received chest radiation, especially those treated decades ago when shielding techniques were less refined, are at risk for radiation-related cardiac complications, including constrictive pericarditis, premature coronary disease, valve disease, and conduction system disease. Routine screening for asymptomatic patients isn't standardized, but any new cardiac symptoms in a patient with a chest radiation history deserve thorough evaluation, including consideration of constrictive disease. The European Association of Cardiovascular Imaging has published recommendations for surveillance imaging in this population.

Can I have both constrictive and restrictive disease at the same time?

Occasionally, yes. Some patients have a "mixed" picture with both processes contributing. Patients with prior cardiac surgery who later develop amyloidosis are one example. Patients with cardiac sarcoidosis can have both granulomatous infiltration of the myocardium and pericardial involvement. The diagnostic challenge in these patients is sorting out which component is contributing more, since the treatments differ. Specialized centers with expertise in both pericardial and infiltrative disease can usually figure this out.

My BNP is very high. What does that mean?

A markedly elevated BNP or NT-proBNP, especially levels in the thousands, is more consistent with restrictive cardiomyopathy than with pure constrictive pericarditis. The reason is that BNP is produced by stretched myocardium, and restrictive disease involves stretching of diseased heart muscle, while constrictive disease involves restriction from outside. This is a useful clue, but it's not perfectly specific, since both diseases can produce elevated BNP, and BNP rises with many other conditions including kidney disease, age, and obesity. Use it as one piece of the puzzle, not as a single diagnostic test.

If I have ATTR amyloidosis, will my children get it?

It depends on whether your ATTR is hereditary or wild-type. Wild-type ATTR is age-related and not inherited; your children are not at increased risk from your wild-type disease. Hereditary ATTR follows an autosomal dominant inheritance pattern, meaning each first-degree relative has roughly a 50 percent chance of inheriting the mutated gene. Genetic testing is available, and family members of patients with hereditary ATTR should be offered testing. Carriers of the mutation can be monitored with serial cardiac imaging to detect early disease, since starting treatment before substantial cardiac damage develops produces better outcomes than starting after symptoms appear.

A Final Note From Me

The constrictive-versus-restrictive question is one of the more satisfying diagnostic puzzles in cardiology because the workup is well-established, the treatments are dramatically different, and getting the right answer can transform a patient's trajectory. Constrictive pericarditis caught early and managed with pericardiectomy is curable. ATTR amyloidosis caught early and treated with tafamidis or vutrisiran can be stabilized for years. Cardiac sarcoidosis caught early and treated with immunosuppression often goes into remission. The opposite is also true: missed diagnoses progress, sometimes beyond the point where any treatment can fully reverse the damage.

If you have unexplained heart failure with preserved ejection fraction, especially with biatrial enlargement, elevated filling pressures, or a history that includes prior cardiac surgery, chest radiation, or systemic disease, push for the workup that distinguishes constrictive from restrictive physiology. Cardiac MRI is usually the highest-yield first test. Right heart catheterization with simultaneous left and right pressures is the definitive hemodynamic study when imaging is ambiguous. Specific blood work (PYP scan for amyloidosis, free light chains, ferritin, ACE level) targets the most common restrictive causes.

If you've been given a diagnosis of constrictive pericarditis or restrictive cardiomyopathy, the most important thing you can do is partner with a cardiologist who has experience with these conditions. The disease-specific management has evolved rapidly over the last decade, and the right team will know about the newest treatment options for your specific cause. The patients I worry about are the ones who got a vague "diastolic heart failure" diagnosis without anyone digging into the underlying mechanism. The patients I'm hopeful about are the ones who got a precise diagnosis and a targeted treatment plan, and who stayed engaged with their care over time.

References

1. Adler, Yehuda, Philippe Charron, Massimo Imazio, et al. "2015 ESC Guidelines for the Diagnosis and Management of Pericardial Diseases." European Heart Journal 36, no. 42 (2015): 2921-2964.

2. Welch, Tara D., E. Wesley Ling, Joseph J. Maleszewski, et al. "Echocardiographic Diagnosis of Constrictive Pericarditis: Mayo Clinic Criteria." Circulation: Cardiovascular Imaging 7, no. 3 (2014): 526-534.

3. Talreja, Deepak R., Robert A. Nishimura, Jae K. Oh, and James F. Glockner. "Constrictive Pericarditis in 26 Patients with Histologically Normal Pericardial Thickness." Circulation 108, no. 15 (2003): 1852-1857.

4. Maron, Barry J., Jeffrey A. Towbin, Gaetano Thiene, et al. "Contemporary Definitions and Classification of the Cardiomyopathies." Circulation 113, no. 14 (2006): 1807-1816.

5. Maurer, Mathew S., Jeffrey H. Schwartz, Balarama Gundapaneni, et al. "Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy." New England Journal of Medicine 379, no. 11 (2018): 1007-1016.

6. Adam, Robert D., Anthony A. Coats, and Brendan S. Madden. "Recent Advances in the Diagnosis and Management of Cardiac Amyloidosis: A Narrative Review." Cardiology and Therapy 11, no. 1 (2022): 19-33.

7. Geske, Jeffrey B., Carmela D. Tan, Hartzell V. Schaff, and Rick A. Nishimura. "Differentiation of Constriction and Restriction." Journal of the American College of Cardiology 73, no. 17 (2019): 2329-2347.

8. Murashita, Takashi, Hartzell V. Schaff, Joseph A. Daly, et al. "Experience with Pericardiectomy for Constrictive Pericarditis over Eight Decades." Annals of Thoracic Surgery 104, no. 3 (2017): 742-750.

9. Maleszewski, Joseph J., Heidi M. Connolly, Aimee N. Christianson, and W. Edward Wirzba. "Pericardial Disease: A Diagnostic and Treatment Approach." Circulation 138, no. 22 (2018): 2477-2491.

10. Kasper, Edward K., Sharon Hare, Phillip A. Arnett, et al. "The Causes of Dilated Cardiomyopathy: A Clinicopathologic Review of 673 Consecutive Patients." Journal of the American College of Cardiology 23, no. 3 (1994): 586-590.

Published on damianrasch.com. The above information was composed by Dr. Damian Rasch, drawing on individual insight and bolstered by digital research and writing assistance. The information is for educational purposes only and does not constitute medical advice.